Review
Dermatology
Arsh Patel, Jane S. Kim, Jason Liss, Lauren Howard, Sin-Ho Jung, Meenal Kheterpal
Summary: Management of patients with locally advanced basal cell carcinoma using traditional strategies has shown suboptimal outcomes. Targeted treatments, including hedgehog inhibitor therapy, have limitations as monotherapy. Evidence-based outcomes from literature support the use of adjunctive therapies post-HHIT to improve treatment response in laBCC patients.
DERMATOLOGIC THERAPY
(2021)
Review
Oncology
Gianluca Nazzaro, Valentina Benzecry, Maria A. Mattioli, Nerina Denaro, Giada A. Beltramini, Angelo V. Marzano, Emanuela Passoni
Summary: Basal cell carcinoma (BCC) is a common type of malignancy. Locally advanced BCC (laBCC) is an aggressive form of BCC that cannot be treated with surgery or radiotherapy. Sonidegib, a Hedgehog inhibitor, has shown efficacy in treating laBCCs. This study reports the experience with Sonidegib treatment in laBCC patients using retrospectively collected data.
Review
Biochemistry & Molecular Biology
Ngoc Minh Nguyen, Jungsook Cho
Summary: This review discusses the importance of the Hedgehog (Hh) signaling pathway in cancer, the emergence of Hh pathway inhibitors, and the mechanisms of drug resistance. Additionally, strategies to overcome resistance are addressed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Ralf Gutzmer, Caroline Robert, Carmen Loquai, Dirk Schadendorf, Nicholas Squittieri, Ramon Arntz, Serena Martelli, Reinhard Dummer
Summary: Overall, applying ERIVANCE-like criteria to patients with laBCC receiving sonidegib 200 mg daily yielded higher response rates compared to mRECIST criteria.
Article
Oncology
Lucie Meynard, Derek Dinart, Blandine Delaunay, Aude Flechon, Carolina Saldana, Felix Lefort, Gwenaelle Gravis, Antoine Thiery-Vuillemin, Mathilde Cancel, Elodie Coquan, Sylvain Ladoire, Denis Maillet, Frederic Rolland, Elouen Boughalem, Sophie Martin, Mathieu Laramas, Laurence Crouzet, Baptiste Abbar, Sabrina Falkowski, Damien Pouessel, Guilhem Roubaud
Summary: This study assessed the efficacy of chemotherapy re-challenge after immune checkpoint inhibitors (ICIs) in patients with locally advanced or metastatic urothelial carcinoma and compared it with second-line chemotherapy without previous ICIs. The results showed that chemotherapy re-challenge after ICIs achieved similar objective response rates and progression-free survival as second-line chemotherapy without previous ICIs, with an acceptable safety profile.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Cora N. Sternberg, Ian D. Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H. Barrios, Pamela Salman, Oleg A. Gladkov, Alexander Kavina, Juan J. Zarba, Mei Chen, Lauren McCann, Lini Pandite, Debasish F. Roychowdhury, Robert E. Hawkins
Summary: This study evaluated the efficacy and safety of Pazopanib in the treatment of advanced renal cell carcinoma. The results showed significant improvement in progression-free survival and tumor response with Pazopanib compared to placebo.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Viola K. DeTemple, Jessica C. Hassel, Michael M. Sachse, Imke Grimmelmann, Ulrike Leiter, Christoffer Gebhardt, Julia Eckardt, Claudia Pfoehler, Yenny Angela, Hanna Huebbe, Ralf Gutzmer
Summary: For patients with advanced basal cell carcinoma (aBCC), treatment options are limited. This study found that HHI reinduction after failure of first-line HHIs and second-line PD1i can be an effective treatment option for a subgroup of patients with aBCC. Therefore, it represents a feasible treatment choice.
Article
Dermatology
Andrew C. Krakowski, Farhaan Hafeez, Alan Westheim, Eva Y. Pan, Melissa Wilson
Summary: Basal cell carcinoma is the most common human cancer, with millions of cases diagnosed annually. UV exposure and genetic mutations are directly related to the development of this cancer. Besides genetic factors, age, gender, occupational hazards, radiation, and immunosuppression are also important risk factors.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Dermatology
Alessia Villani, Gabriella Fabbrocini, Giuseppe Micali, Luigi Fornaro, Luca Potestio, Massimiliano Scalvenzi
Summary: This study evaluated the effectiveness and safety of sonidegib in the management of locally advanced basal cell carcinoma (BCC) in the periocular region. The results suggest that sonidegib is a valuable and safe option for periocular BCC management.
DERMATOLOGY AND THERAPY
(2023)
Review
Oncology
Markus Heppt, Christoffer Gebhardt, Jessica C. Hassel, Mareike Alter, Ralf Gutzmer, Ulrike Leiter, Carola Berking
Summary: This article reviews treatment adjustments and novel therapeutic strategies for locally advanced basal cell carcinoma (laBCC). Hedgehog pathway inhibitors (HHIs) are the first-line therapy, but long-term treatment may cause toxicity and impact quality of life. Optimization of current treatment schedules and exploration of new combination strategies and drugs are urgently needed for laBCC.
Review
Chemistry, Medicinal
Neha Gupta, Emily S. Ruiz
Summary: Basal cell carcinoma is the most common cancer in Caucasians and requires a multi-modal approach for treatment.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Oncology
Yoon-Koo Kang, Suzanne George, Robin L. Jones, Piotr Rutkowski, Lin Shen, Olivier Mir, Shreyaskumar Patel, Yongjian Zhou, Margaret von Mehren, Peter Hohenberger, Victor Villalobos, Mehdi Brahmi, William D. Tap, Jonathan Trent, Maria A. Pantaleo, Patrick Schoeffski, Kevin He, Paggy Hew, Kate Newberry, Maria Roche, Michael C. Heinrich, Sebastian Bauer
Summary: Avapritinib, a potent inhibitor of KIT and PDGFRA mutant kinases, showed clinical activity in GISTs with specific mutations. The VOYAGER study comparing avapritinib and regorafenib in advanced GIST patients did not find a significant difference in median progression-free survival, but showed similar overall survival and safety profiles between the two treatments.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Mitesh J. Borad, Li-Yuan Bai, Donald Richards, Kabir Mody, Joleen Hubbard, Sun Young Rha, John Soong, Daniel McCormick, Emmett Tse, Daniel O'Brien, Ahmad Bayat, Daniel Ahn, S. Lindsey Davis, Joon Oh Park, Do-Youn Oh
Summary: This study investigates the safety and efficacy of silmitasertib in combination with gemcitabine and cisplatin for the treatment of cholangiocarcinoma. The results show promising preliminary evidence of efficacy for the first-line treatment of locally advanced/metastatic cholangiocarcinoma.
Article
Oncology
Raoul Tibes, Heidi E. Kosiorek, Amylou C. Dueck, Jeanne Palmer, Lisa Sproat, James Bogenberger, Shahrukh Hashmi, Ruben Mesa, William Hogan, Mark R. Litzow, Aref Al-Kali
Summary: In this study, the combination of azacitidine and Sonidegib showed efficacy in newly diagnosed AML/MDS patients, but had limited response in relapsed/refractory cases of myeloid neoplasms.
Article
Immunology
Wei Deng, Xiao Chang, Xin Dong, Yuting Zhao, Dan Yang, Leilei Jiang, Anhui Shi, Huiming Yu, Rong Yu, Zefen Xiao, Weihu Wang
Summary: Induction immunochemotherapy followed by radiotherapy may improve locoregional control and survival outcomes for patients with unresectable locally advanced or metastatic esophageal cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Zoubir Ouhib, Michael Kasper, Jose Perez Caatayud, Silvia Rodriguez, Ajay Bhatnagar, Sujatha Pais, John Strasswimrner
Article
Dermatology
Murad Alam, Rohit Kakar, Michael Nodzenski, Omer Ibrahim, Wareeporn Disphanurat, Diana Bolotin, Judy H. Borovicka, Natalie Pace, Tina S. Alster, Kenneth A. Arndt, Kenneth R. Beer, Joshua M. Berlin, Leonard J. Bernstein, Lori A. Brightman, Kimberly Butterwick, Sue Ellen Cox, Vera Chotzen, Sabrina G. Fabi, Richard E. Fitzpatrick, Roy G. Geronemus, Mitchel P. Goldman, William F. Groff, Michael S. Kaminer, Suzanne Kilmer, Thomas E. Rohrer, Elizabeth L. Tanzi, Susan K. Silva, Simon S. Yoo, Susan H. Weinkle, John Strasswimmer, Emily Poon, Jeffrey S. Dover
Editorial Material
Dermatology
John M. Strasswimmer
Letter
Dermatology
Peter D. Simone, Jamie M. Schwarz, John M. Strasswimmer
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2016)
Letter
Dermatology
Audrey A. Jacobsen, Yotam B. Papo, Robert Sarro, Kurt Weisse, John Strasswimmer
Article
Dermatology
Audrey A. Jacobsen, Ana Galvan, Claudina Canaan Lachapelle, Cheryl B. Wohl, Robert S. Kirsner, John Strasswimmer
Article
Dermatology
Audrey A. Jacobsen, Jezabel Maisonet, Robert S. Kirsner, John Strasswimmer
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2017)
Letter
Dermatology
Audrey A. Jacobsen, Andre R. Kydd, John Strasswimmer
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2017)
Article
Obstetrics & Gynecology
John Strasswimmer, Benjamin Latimer, Steven Ory
FERTILITY AND STERILITY
(2014)
Article
Dermatology
Joshua M. Berlin, Allison H. Cassedy, Kristen Zoppi, John Strasswimmer, Mary Jean de Guzman, Ariel Abraham, Dan Mockler, Jason Cohen, David Silverstein, Christy Wang, Iona Chapman, Nnenna Agim
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2013)
Article
Dermatology
Sara A. Fox, Ashley A. Shanblatt, Hugh Beckman, John Strasswimmer, Andrew C. Terentis
LASERS IN SURGERY AND MEDICINE
(2014)
Article
Dermatology
Murad Alam, Andy Lee, Omar A. Ibrahimi, Natalie Kim, Jeremy Bordeaux, Karen Chen, Scott Dinehart, David J. Goldberg, William Hanke, George J. Hruza, Kishwer S. Nehal, Suzanne M. Olbricht, Jeffrey Orringer, Thomas E. Rohrer, Noah S. Scheinfeld, Chrysalyne D. Schmults, John M. Strasswimmer, James S. Taylor, Simon Yoo, Michael Nodzenski, Emily Poon, Todd Cartee
Article
Oncology
Chirag Shah, Zoubir Ouhib, Mitchell Kamrava, Shlomo A. Koyfman, Shauna R. Campbell, Ajay Bhatnagar, Joycelin Canavan, Zain Husain, Christopher A. Barker, Gil'ad N. Cohen, John Strasswimmer, Nikhil Joshi
Letter
Dermatology
Audrey A. Jacobsen, Jamie Schwarz, Carlos H. Nousari, John Strasswimmer
DERMATOLOGIC SURGERY
(2017)